Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistance
Leukemia · 2025-01 · 39 (1) · 189-198
DOI: 10.1038/s41375-024-02431-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Leukemia, online erschienen am 18.10.2024. Verfasst von Clarissa Corinaldesi und 24 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Cancer Genetics, Columbia University, New York, NY, USA. Hauptthemen laut MEDLINE: Burkitt Lymphoma, Biomarkers, Tumor, Drug Resistance, Neoplasm, Single-Cell Analysis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI), NCI NIH HHS, Lymphoma Research Foundation.
Abstract (Originalsprache)
Burkitt lymphoma (BL) is the most frequent B-cell lymphoma in pediatric patients. While most patients are cured, a fraction of them are resistant to therapy. To investigate BL heterogeneity and the features distinguishing therapy responders (R) from non-responders (NR), we analyzed by single-cell (sc)-transcriptomics diagnostic EBV-negative BL specimens. Analysis of the non-tumor component revealed a predominance of immune cells and a small representation of fibroblasts, enriched in NR. Tumors displayed patient-specific features, as well as shared subpopulations that expressed transcripts related to cell cycle, signaling pathways and cell-of-origin signatures. Several transcripts were differentially expressed in R versus NR. The top candidate, Tropomyosin 2 (TPM2), a member of the tropomyosin actin filament binding protein family, was confirmed to be significantly higher in NR both at the transcript and protein level. Stratification of patients based on TPM2 expression at diagnosis significantly correlated with prognosis, independently of TP53 mutations. These results indicate that BL displays transcriptional heterogeneity and identify candidate biomarkers of therapy resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Cancer Genetics, Columbia University, New York, NY, USA.
- Maternal and Child Health Department, University-Hospital of Padova, Padova, Italy.
- Istituto di Ricerca Pediatrica Citta' della Speranza, Padova, Italy.
- Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
- Dana-Farber Cancer Institute, Boston, MA, USA.
- Department of Medical Science, University of Torino, Torino, Italy.
Förderung
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
- NCI NIH HHS
- Lymphoma Research Foundation
- Fondazione Città della Speranza
Zitieren
APA
Corinaldesi, C., Holmes, A. B., Martire, G., Tosato, A., Rizzato, D., Lovisa, F., Gallingani, I., Shen, Q., Ferrone, L., Harris, M., Davies, K., Molinaro, L., Mortara, U., Dei Tos, A. P., Ofori, K., D'Amore, E. S. G., Chiarle, R., Ngan, B., Carraro, E., …, & Basso, K. (2025). Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistance. Leukemia, 39(1), 189-198. https://doi.org/10.1038/s41375-024-02431-3
Vancouver
Corinaldesi C, Holmes AB, Martire G, Tosato A, Rizzato D, Lovisa F, et al. Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistance. Leukemia. 2025;39(1):189-198. doi:10.1038/s41375-024-02431-3
BibTeX
@article{Corinaldesi2025,
author = {Corinaldesi, Clarissa and Holmes, Antony B and Martire, Gaia and Tosato, Anna and Rizzato, Domenico and Lovisa, Federica and Gallingani, Ilaria and Shen, Qiong and Ferrone, Lavinia and Harris, Marian and Davies, Kimberly and Molinaro, Luca and Mortara, Umberto and Dei Tos, Angelo Paolo and Ofori, Kenneth and D'Amore, Emanuele S G and Chiarle, Roberto and Ngan, Bo and Carraro, Elisa and Pillon, Marta and Hussein, Shafinaz and Bhagat, Govind and Pizzi, Marco and Mussolin, Lara and Basso, Katia},
title = {Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistance},
journal = {Leukemia},
year = {2025},
volume = {39},
number = {1},
pages = {189--198},
doi = {10.1038/s41375-024-02431-3}
}
EUVIMED